Relmada Therapeutics, Inc
Price
FilingsNewest: 8-K, Other eventsSep 8 →Insiders4 insiders bought $4.0M in 10 open-market buys. No sales.→HoldersJupiter Topco 10.5%BlackRock 7.0%Squadron 6.9%→Financing →PeersClosest companies: NRXP, RKTO, ENVB→
From the filings
Figures
- Net income
- −$61.9Mlast 12 months
- Operating cash flow
- −$42.8Mlast 12 months
- Cash and equivalents
- $11.3Mat the last balance sheet
- Shares outstanding
- 106.7M shareson issue